Activation of the PI3K/AKT pathway, IL-6/JAK2/STAT3 pathway, and stem cell-like characteristics contribute to the poor outcomes of metastatic breast cancers [8, 9]. This evidence concerns the gene JAK2 and breast carcinoma.